Dishman Carbogen Amcis reports strong performance, outlines growth strategy

Dishman Carbogen Amcis (DCAL) has reported strong financial performance, with LTM Q1 FY26 revenue reaching INR 28,958 Mn, reflecting a 9.1% revenue CAGR from FY21-25. The company’s EBITDA margin stood at 20.1% for LTM Q1 FY26, with an orderbook of INR 23,094 Mn for FY26. The company also highlighted its fully invested infrastructure, including a HiPo facility in Bavla, India, which is one of the largest in Asia, and a manufacturing scale of 916 KL across 10 sites.

The company's CDMO business shows particular strength, with LTM Q1 FY26 revenue of INR 24,800 Mn. CDMO services, including API and formulations, account for 85.7% of total revenue. Key initiatives for growth include expanding into niche high-growth areas like ADCs, integrating operations between Dishman and CARBOGEN AMCIS, and co-investment models with large pharmaceutical companies.

Dishman Carbogen Amcis emphasized its robust execution track record across high-value therapy areas such as oncology, antibiotic/anti-viral, and ophthalmology, boasting 28 commercialized molecules and 12 late-phase III molecules. The company is actively pursuing operational excellence, green chemistry, and IT transformation to drive further growth and efficiency.